Celebrex Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Celebrex Indications
Indications
Celebrex Dosage and Administration
Adult
Children
Renal Impairment
-
Severe renal insufficiency: not recommended.
Hepatic Impairment
-
Moderate hepatic impairment (Child-Pugh B): reduce dose by 50%.
-
Severe hepatic impairment: not recommended.
Other Modifications
Females and Males of Reproductive Potential
-
Infertility for Females: May delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Consider withdrawal of NSAIDs, including celecoxib, in women who have difficulties conceiving or who are undergoing investigation of infertility.
Poor Metabolizers of CYP2C9 Substrates
-
Known or suspected poor CYP2C19 metabolizers: give Celebrex starting with half the lowest recommended dose.
-
Consider alternative therapies for the treatment of JRA in pediatric patients who are CYP2C19 poor metabolizers.
Celebrex Contraindications
Contraindications
Celebrex Boxed Warnings
Boxed Warning
Celebrex Warnings/Precautions
Warnings/Precautions
Celebrex Pharmacokinetics
Absorption
-
Peak plasma levels: ~3 hours after an oral dose.
Distribution
-
~97% protein bound primarily to albumin.
-
Volume of distribution: ~400 L.
Elimination
-
Half-life: 11.2 hours.
-
Eliminated predominantly by hepatic metabolism.
-
Fecal (57%), renal (27%).
-
Plasma clearance: ~500 mL/min.
Celebrex Interactions
Interactions
Celebrex Adverse Reactions
Adverse Reactions
Celebrex Clinical Trials
Celebrex Note
Not Applicable
Celebrex Patient Counseling
Cost Savings Program
Celebrex Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Celebrex Indications
Indications
Celebrex Dosage and Administration
Adult
Children
Renal Impairment
-
Severe renal insufficiency: not recommended.
Hepatic Impairment
-
Moderate hepatic impairment (Child-Pugh B): reduce dose by 50%.
-
Severe hepatic impairment: not recommended.
Other Modifications
Females and Males of Reproductive Potential
-
Infertility for Females: May delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Consider withdrawal of NSAIDs, including celecoxib, in women who have difficulties conceiving or who are undergoing investigation of infertility.
Poor Metabolizers of CYP2C9 Substrates
-
Known or suspected poor CYP2C19 metabolizers: give Celebrex starting with half the lowest recommended dose.
-
Consider alternative therapies for the treatment of JRA in pediatric patients who are CYP2C19 poor metabolizers.
Celebrex Contraindications
Contraindications
Celebrex Boxed Warnings
Boxed Warning
Celebrex Warnings/Precautions
Warnings/Precautions
Celebrex Pharmacokinetics
Absorption
-
Peak plasma levels: ~3 hours after an oral dose.
Distribution
-
~97% protein bound primarily to albumin.
-
Volume of distribution: ~400 L.
Elimination
-
Half-life: 11.2 hours.
-
Eliminated predominantly by hepatic metabolism.
-
Fecal (57%), renal (27%).
-
Plasma clearance: ~500 mL/min.
Celebrex Interactions
Interactions
Celebrex Adverse Reactions
Adverse Reactions
Celebrex Clinical Trials
Celebrex Note
Not Applicable
Celebrex Patient Counseling
Cost Savings Program
Celebrex Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Celebrex Indications
Indications
Celebrex Dosage and Administration
Adult
Children
Renal Impairment
-
Severe renal insufficiency: not recommended.
Hepatic Impairment
-
Moderate hepatic impairment (Child-Pugh B): reduce dose by 50%.
-
Severe hepatic impairment: not recommended.
Other Modifications
Females and Males of Reproductive Potential
-
Infertility for Females: May delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women. Consider withdrawal of NSAIDs, including celecoxib, in women who have difficulties conceiving or who are undergoing investigation of infertility.
Poor Metabolizers of CYP2C9 Substrates
-
Known or suspected poor CYP2C19 metabolizers: give Celebrex starting with half the lowest recommended dose.
-
Consider alternative therapies for the treatment of JRA in pediatric patients who are CYP2C19 poor metabolizers.
Celebrex Contraindications
Contraindications
Celebrex Boxed Warnings
Boxed Warning
Celebrex Warnings/Precautions
Warnings/Precautions
Celebrex Pharmacokinetics
Absorption
-
Peak plasma levels: ~3 hours after an oral dose.
Distribution
-
~97% protein bound primarily to albumin.
-
Volume of distribution: ~400 L.
Elimination
-
Half-life: 11.2 hours.
-
Eliminated predominantly by hepatic metabolism.
-
Fecal (57%), renal (27%).
-
Plasma clearance: ~500 mL/min.
Celebrex Interactions
Interactions
Celebrex Adverse Reactions
Adverse Reactions
Celebrex Clinical Trials
Celebrex Note
Not Applicable
Celebrex Patient Counseling
Cost Savings Program
Images
